A director at Floridienne S.A. sold 2,000 shares at 510.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
We increased our FY24 numbers substantially as Floridienne recorded strong growth in 9M24 y/y as 9M24 sales came in at € 502.4m (+25% y/y), and 9M24 EBITDA was €84.9m (+€35.9m y/y) and a 9M24 net result came in at € 17.1m (+€8.0m y/y). Floridienne indicated that this was mainly thanks to the dynamism of its historical activities and the successful integration of Biotrop. The Foot Division is succeeding in increasing its profitability. BioFirst is growing significantly on its historical market of...
Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the anti-C...
Nous avons organisé la semaine dernière un Expert Access autour de la sclérose en plaques (SEP) avec la participation du Dr Géraldine Androdias, médecin neurologue au CHU de Lyon. Le Dr Androdias a présenté les points saillants du congrès de l’ECTRIMS 2024 ainsi que les nouvelles tendances dans la prise en charge de la maladie. Nous retenons un besoin insatisfait dans les formes progressives et secondairement progressives, un vrai intérêt de la classe des BTKi avec le passage accru de...
Below are the highlights from the conference call. Akzo's 3Q adjusted EBITDA dropped by 5% which was close to our forecasts and 2% below consensus. Akzo adjusted its FY24 adjusted EBITDA guidance from ‘towards the lower end of a € 1.5-1.65bn range' to ‘around €1.5bn' with consensus at € 1499m and KBCS at € 1513m. FY24 leverage guidance is adjusted from around 2.3x to around 2.7x. The mid term guidance of at least 16% adjusted EBITDA margin is maintained, which represents a 260bps increase from 2...
>Weak adj. EBITDA progression, now mainly due to Coatings - AkzoNobel posted a relatively weak Q3 24 driven by slightly positive volumes (neutral price/mix). While the group gross margin improved yoy for the quarter, higher restructuring costs and opex inflation continued to impact operating earnings. Overall Q3 group revenues and adj. EBITDA came in at € 2,668m and € 394m respectively; revenues were -3% below ccs estimates and adj. EBITDA -2%, with the main drag at C...
AkzoNobel: Slight miss on 3Q24, larger miss on year-end leverage Allfunds Group PLC: Strong NNM beat ASM International: Preview 3Q24; probably not too bad Azelis: 3Q24 results preview Heineken: Yet another miss Kinepolis: 3Q24 preview Philips: Preview 3Q24, some upside risk to margins Proximus: 3Q24 preview Events Calendar
Akzo's 3Q adjusted EBITDA dropped by 5% which was close to our forecasts and 2% below consensus. Akzo adjusted its FY24 adjusted EBITDA guidance from ‘towards the lower end of a € 1.5-1.65bn range' to ‘around € 1.5bn' with consensus at € 1499m and KBCS at € 1513m. FY24 leverage guidance is adjusted from around 2.3x to around 2.7x. The mid term guidance of at least 16% adjusted EBITDA margin is maintained, which represents a 260bps increase from 2023A. Taking into account the volatile track recor...
>Towards the lower end of the guidance - Akzo is set to report results for the third quarter on October 23. For the group, we forecast Q3 24 revenues of € 2,770m (+1% yoy, slightly higher than ccs) and € 407m adj. EBITDA, the latter in line with management guidance (‘similar to Q2 24’). The company maintained FY24 guidance at H1 24 results (adj. EBITDA € 1.50-1.65bn) though is now projecting to hit the lower end of the range. If end-markets remain weak (e.g. no EMEA, ...
The launch of a portfolio review highlights the focus on the core Coatings businesses, whilst Akzo will take a more opportunistic approach with regards to its Decorative Paints business. Leverage is still reasonably high at 2.9x at the moment, although the company expects to end the year at c. 2.3x. We remind that Akzo lowered FY24 adjusted EBITDA guidance at the time of the 2Q results release towards the lower end of its initial € 1.5-1.65bn guidance range (FY23: €1.43bn). Taking into account t...
We update our model to reflect the slight miss in 2Q24 results due to higher OPEX inflation and AkzoNobel guiding towards the low end of its 2024F Adj. EBITDA guidance. We stick to our HOLD rating and we reduce our target price to €61 per share from €64, as we believe that mid-term growth targets are well captured by consensus expectations.
Akzo's 2Q adjusted EBITDA was up only 1% y/y and fell short to our and consensus forecasts by respectively 8% and 3% on fairly weak volumes (+1% y/y) and higher opex. Akzo lowered FY24 adjusted EBITDA guidance, now expected to land at the lower end of its initial € 1.5-1.65bn guidance range. We have lowered our FY24 forecasts by c. 4% and our FY25 forecast by c 2%. The mid term guidance of at least 16% adjusted EBITDA margin is maintained, which represents a 260bps increase from 2023A. Despite t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.